Godavari Biorefineries share price hits upper circuit despite rising 30% in one month; here's why
'Godavari Biorefineries Ltd, through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by the China National Intellectual Property Administration (CNIPA), China's patent and trademark office, for its novel anti-cancer molecule — HYDROXY-1,4-NAPHTHALENEDIONE,' the company informed the BSE through the filing.
Godavari Biorefineries is a major producer of ethanol and ethanol-based chemicals in India. The company manufactures bio-based chemicals, sugar, rectified spirits, ethanol, other grades of alcohol and power, according to the official website.
(This is a developing story. Please check back for updates.)
Read all stories by Anubhav Mukherjee
Disclaimer: This story is for educational purposes only. The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
29 minutes ago
- Economic Times
Hims & Hers Q2 revenue drop shakes stock—Hims crashes 11% after first-ever revenue decline, is the weight-loss drug hype finally fading?
Hims & Hers Health (NYSE: HIMS) saw its stock plunge over 11% after the company reported its Q2 2025 earnings, marking its first-ever sequential revenue decline. While revenue jumped 73% year-over-year to $544.8 million, it still fell short of Wall Street's expectations of $552 million, and notably dropped from $586 million in Q1. The miss has rattled investor confidence, especially as GLP-1 weight-loss drug sales, a key growth driver, showed signs of slowing amid regulatory pressure and legal setbacks. Synopsis Hims & Hers stock dropped a sharp 11% after the company missed Q2 2025 revenue estimates, raising concerns about its booming weight-loss drug business. While year-over-year sales jumped 73%, revenue fell sequentially for the first time, causing investor worry. The company brought in $544.8 million, short of forecasts, with much of it tied to its GLP-1 obesity drug offerings. Hims & Hers Health (NYSE: HIMS), the fast-growing telehealth company known for its personalized care plans and buzzy entry into the weight-loss market, saw its stock drop by over 11% after reporting second-quarter 2025 earnings. While revenue jumped 73% year-over-year, the company missed Wall Street expectations and posted its first-ever sequential revenue decline, raising questions about the future of its GLP-1 obesity drug business. ADVERTISEMENT Despite its rapid annual growth, Hims & Hers posted Q2 revenue of $544.8 million, missing the analyst estimate of $552 million. The real concern? Revenue dropped from $586 million in Q1, marking the first quarter-over-quarter decline since the company went public. The stock currently trades at $63.35, regaining some ground after hitting an intraday low of $54.82. Despite opening at $64.00, it remains volatile, with an intraday high of $65.54. ALSO READ: Bullish IPO debut: Peter Thiel-backed crypto giant targets $4.2B valuation—is the new crypto wave knocking on Wall Street's door? The market reacted sharply to the company's revenue miss—$544.8 million vs. $552 million expected—even though earnings per share beat expectations and subscriber numbers remained strong. Most of the company's revenue stemmed from its GLP-1-based obesity and diabetes treatments, a booming but increasingly scrutinized business segment. ALSO READ: Palantir stock soars after $1B Q2 earnings crush forecasts as AI demand fuels 110% YTD surge—now S&P 500's top performer ADVERTISEMENT With regulatory pressures, lawsuits from Novo Nordisk, and tighter FDA rules on compounded semaglutide, Hims faces headwinds in its fastest-growing segment. However, with a market cap of over $6.5 billion, a P/E ratio of 39.93, and forward-looking confidence via its Zava acquisition, the company is still betting big on growth in both the U.S. and Europe. Current Price : $63.35 : $63.35 Day Range : $54.82 – $65.54 : $54.82 – $65.54 Open : $64.00 : $64.00 Market Cap: $6.56 Billion P/E Ratio : 39.93 : 39.93 Volume: 35.5M Investors were caught off guard, as the slowdown came amid soaring demand for weight-loss drugs like semaglutide, a compound similar to the active ingredient in Wegovy and Ozempic. ADVERTISEMENT On the profit front, Hims reported an adjusted EPS of $0.19, beating the Street's expectation of $0.15. However, the revenue miss overshadowed this earnings win. Investors appeared more concerned about the underlying business momentum, particularly in the obesity treatment space, which has been a major driver of Hims' recent growth. ADVERTISEMENT Hims' biggest growth story in recent quarters has been its expansion into GLP-1 weight-loss treatments, which brought in around $190 million in Q2 alone. However, a few red flags have emerged: Regulatory uncertainty : With the FDA rolling back flexibility on compounded versions of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. : With the FDA rolling back flexibility on of semaglutide, questions are mounting about how long Hims can rely on this segment for revenue. Legal challenges : The company recently ended its supply relationship with Novo Nordisk , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. : The company recently ended its supply relationship with , the maker of Wegovy, and is now facing lawsuits over how it marketed compounded alternatives. Competitive pressure: Big players like Eli Lilly and Novo Nordisk are dominating the branded drug market, making it harder for telehealth companies offering generics to compete on pricing and trust. Despite the Q2 shortfall, Hims & Hers stuck to its full-year outlook. The company reaffirmed its 2025 guidance of $2.3 billion to $2.4 billion in revenue and $295 million to $335 million in adjusted EBITDA. ADVERTISEMENT A big reason? The Zava acquisition, a European telehealth platform, which is expected to contribute around $50 million in new revenue this year. This suggests Hims is betting heavily on international growth to offset some of its domestic uncertainty. One bright spot in the report was Hims' growing subscriber base. The company now serves over 2.4 million active subscribers, with nearly 70% enrolled in personalized treatment plans that span weight loss, hair care, sexual health, and mental wellness. CEO Andrew Dudum emphasized that the company is leaning deeper into its long-term strategy of personalized digital healthcare, aiming to build loyalty and customer lifetime value across multiple product categories. If you're following Hims & Hers stock or investing in telehealth companies focused on the obesity drug boom, here are four key things to monitor: Future of compounded GLP-1s: Regulatory and legal outcomes could limit Hims' ability to sell compounded semaglutide at scale. Profitability trends: Will margins hold up as more competition floods the market and Hims scales its personalized offerings? Subscriber growth and retention: Continued engagement in non-weight loss categories will be key to long-term stability. Zava integration: The success or failure of this acquisition could make or break Hims' international ambitions. Hims & Hers Health has come a long way as a digital-first wellness brand with a bold strategy around weight-loss drugs and personalized healthcare. But the 11% stock drop shows investor sentiment is shifting, especially as its flagship obesity business faces regulatory hurdles and supply uncertainty. For now, the company's strong year-over-year growth and firm 2025 guidance offer some reassurance. But with rising competition, tighter FDA rules, and legal pressure, Hims will need to prove that its success isn't just tied to a single product wave—but a durable, trusted digital care ecosystem. What caused Hims & Hers stock to fall 11% after Q2 earnings? The company missed revenue estimates and saw its first-ever sequential drop in sales. Is the Hims weight-loss drug business facing trouble in 2025? Yes, due to FDA scrutiny and legal issues around compounded semaglutide. (You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. NEXT STORY
Time of India
an hour ago
- Time of India
'End Indian H-1B visas,' says Marjorie Taylor Greene. What this could mean for students and early-career professionals in the US
In a recent post on X, United Sates (US) Congresswoman Marjorie Taylor Greene called for an end to 'Indian H-1B visas replacing American jobs.' The comment, shared on August 4, 2025, has drawn attention across student and professional networks, particularly among Indian nationals studying or working in the US. Greene's statement does not signal a formal policy change, but it adds to the ongoing political debate around work visas and employment pathways for international talent in the US. The H-1B visa , which allows US employers to hire foreign workers in specialised fields, is widely used by Indian graduates after completing their education through student visa programmes. What was said, and in what context Marjorie Taylor Greene, a Republican Congresswoman representing Georgia's 14th district, reposted President Donald Trump 's tweet that called for increased tariffs on Indian exports due to the country's ongoing oil trade with Russia. Her repost included a separate message: 'End Indian H-1B visas replacing American jobs instead'. This statement comes at a time of heightened trade tensions between the US and India, following Trump's announcement that tariffs would be raised in response to India's oil dealings. Though brief, Greene's post is prompting reactions from tech workers, legal professionals, and student communities. It also adds to the broader national conversation around immigration, outsourcing, and the US labour market. With the 2024 presidential election cycle continuing to shape political discourse, topics like employment-based immigration and visa reform remain under close scrutiny. Why Indian students and professionals are paying attention India has long been the largest source of H-1B visa recipients. According to the US Citizenship and Immigration Services (USCIS), nearly 70% of H-1B visas approved in fiscal year 2024 went to Indian nationals. Many of these individuals begin their journey on F-1 student visas, later transitioning to Optional Practical Training (OPT) and applying for H-1B sponsorship. For current students and early-career professionals, the H-1B programme is often viewed as a critical bridge to gaining long-term work experience in the US. While Greene's post does not introduce a legislative proposal, it reflects growing scrutiny in some political circles about how the programme is used. No change in policy, but rhetoric matters It is important to note that no new law or executive order has been introduced to restrict Indian H-1B visa applications. Greene's post is a personal statement, not a formal measure. However, in a politically charged climate, such rhetoric can influence how immigration policy is discussed and potentially shaped. Recent discussions in Congress have included calls for increased transparency in the H-1B lottery process, stronger wage protections for domestic workers, and expanded pathways for Science, technology, engineering, and mathematics (STEM) graduates from US universities. Within that context, statements from elected officials, even when unofficial, can signal what themes may surface in future policy debates. Where this leaves students and applicants in 2025 As of August 2025, students planning to study in the US or currently enrolled on F-1 visas remain unaffected. The Optional Practical Training (OPT) programme and H-1B application processes continue as usual. However, international students and recent graduates are encouraged to stay updated on official USCIS announcements and consult academic advisors or legal experts when planning for post-study employment. While Greene's comment may not have immediate legal consequences, it reflects a viewpoint that could influence public opinion and future discussions on skilled migration. For Indian students and professionals navigating education and employment pathways in the US, staying informed and prepared remains essential. Ready to navigate global policies? Secure your overseas future. Get expert guidance now!
Indian Express
an hour ago
- Indian Express
Delhi: Pay Rs 1.2 lakh to clear outstanding fee, court tells parent as pvt school claims financial situation jeopardised
A Delhi court recently directed a man to pay Rs 1.21 lakh to a private school in the city as the outstanding fee for his child. The Judge was hearing a suit filed by Bluebells International School, which was the defendant for the recovery of the school fee of one of its students. The school had argued that the parent, the plaintiff, was under a legal obligation to make timely and regular payments of the fees. 'Present suit has been filed on October 16, 2024, whereas the cause of action last arose upon the plaintiff on February 7, 2024, when the defendant made the last payment against the outstanding amount,' the court noted in its order dated July 23. 'In view of the foregoing reasons, the present suit is decreed in favour of the plaintiff and against the defendant. The plaintiff is held entitled to recover from the defendant a sum of Rs.1,21,418/- alongwith interest @ 10% per annum from the date of institution of the suit till the realisation of the suit amount,' said Civil Judge Yashu Khurana of Saket Court. It was also argued that the parent had not cleared the dues despite repeated requests and reminders. Stating that its financial situation was being jeopardised, the school also told the court that a legal notice dated May 31, 2024 was issued to the parent. The order comes at a time when the Delhi government has introduced a Bill to regulate fee hikes by private schools in the Assembly amid the ongoing Monsoon Session. The Bill, which has come in the backdrop of protests by parents against arbitrary hikes by private schools, imposes strict penalties on schools that hike fees in an arbitrary manner. Schools will face fines ranging from Rs 1 lakh to Rs 5 lakh for the first time offences and Rs 2 to 10 lakh for repeat violations. Repeat violations may also lead to a loss of the right to increase fees in the future.
